HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

On April 26, 2023 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 2-6, 2023 (Press release, Hookipa Biotech, APR 26, 2023, View Source [SID1234630524]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re excited to present an overview of our ongoing HB-300 Phase 1/2 clinical trial at ASCO (Free ASCO Whitepaper)," said Joern Aldag, Chief Executive Officer at HOOKIPA. "HB-300 is our second oncology immunotherapy program currently in the clinic. We look forward to sharing more about this novel compound as we seek to address unmet clinical needs in prostate cancer."

Details of the presentation are:

HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer
Abstract #TPS5108; Poster Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Saturday, June 3, 2023; 8:00-11:00 am CT
The full abstract will become public at 5:00 pm ET on Thursday, May 25.

About HB-300
HB-300 is an alternating, 2-vector replicating arenaviral immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). HB-300 uses the lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV) as arenaviral backbones, with each expressing two well-defined antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA). HOOKIPA’s approach is designed to focus the immune response against the target antigens and has demonstrated the ability to induce potent antigen-specific T cells responses and anti-tumor activity in preclinical and clinical settings.